Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells $386,500.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total value of $386,500.00. Following the transaction, the chief executive officer now directly owns 863,524 shares in the company, valued at approximately $6,675,040.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Christopher Gibson also recently made the following trade(s):

• On Wednesday, April 3rd, Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.84, for a total transaction of $353,600.00.
• On Thursday, March 28th, Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.10, for a total transaction of $404,000.00.
• On Wednesday, March 6th, Christopher Gibson sold 36,319 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $11.86, for a total transaction of $430,743.34.
• On Wednesday, February 7th, Christopher Gibson sold 48,272 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.22, for a total transaction of $445,067.84.

Recursion Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ RXRX opened at $8.84 on Monday. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.80 and a 52-week high of $16.75. The firm has a fifty day moving average of $9.88 and a 200-day moving average of $9.22. The stock has a market capitalization of $2.07 billion, a PE ratio of -5.70 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The company had revenue of $10.89 million during the quarter, compared to analysts’ expectations of $12.37 million. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RXRX has been the subject of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and set a $17.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. KeyCorp lifted their target price on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Finally, TD Cowen began coverage on shares of Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a “market perform” rating for the company. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $12.75.

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors have recently made changes to their positions in RXRX. ARK Investment Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 200.4% during the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock valued at $203,651,000 after acquiring an additional 13,777,689 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Recursion Pharmaceuticals by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 15,665,210 shares of the company’s stock worth $154,459,000 after buying an additional 158,376 shares in the last quarter. Mubadala Investment Co PJSC acquired a new position in Recursion Pharmaceuticals in the 4th quarter worth $128,041,000. FMR LLC lifted its holdings in Recursion Pharmaceuticals by 134.4% in the 3rd quarter. FMR LLC now owns 10,689,532 shares of the company’s stock worth $81,775,000 after buying an additional 6,129,935 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Recursion Pharmaceuticals by 12.6% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company’s stock valued at $103,317,000 after purchasing an additional 1,159,023 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.